All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s.
A new study funded in part by the Parkinson’s Foundation shows how the loss of brain neurons in Parkinson’s disease (PD) could, in part, result from an attack by a person’s own immune system. Furthermore, the researchers link this attack to alpha-synuclein – the protein that forms toxic clumps in the brain cells of people with PD. The results appear in the June 21 online edition of Nature.
In an early, small clinical trial an experimental drug designed to clear away a toxic protein associated with Parkinson’s disease (PD) was found to be safe in people. This result is a step toward evaluating whether therapies that target the alpha-synuclein protein can slow PD progression. The research appears in the February edition of Movement Disorders.
In studies with laboratory mice, scientists have identified a single molecule, an enzyme called c-Abl, that regulates the build-up of toxic alpha-synuclein protein in brain cells. Such protein clumps, known as Lewy bodies, are the hallmark of Parkinson’s disease (PD). The finding suggests that blocking the enzyme may be an effective approach for new therapies to treat PD. The research appears in the June 27 online edition of The Journal of Clinical Investigation.
In laboratory studies with cells, scientists have identified a new molecule that may be able to help clear toxic protein clumps from the brain in Parkinson’s disease (PD). Its discovery begins a long road of research that potentially lead to a new therapy for PD. The study appears in the July 13 edition of The Journal of Neuroscience.